The Cytel Blog: Perspectives on Enquiry & Evidence

Synthetic control arms (SCAs) are best suited for situations when a single arm trial is run in a patient population..

Scientists at Cytel recently published a paper in the Journal of the American Medical Association (JAMA). Among the..

Earlier this month, my colleagues at Cytel Canada published a paper in JCO Clinical Cancer Informatics, offering a..

In the recent years, Oncology trials are seeing a technological shift that is expected to make them faster and more..

Early stage Phase 2 clinical trials are often designed as multi-stage single arm trials, which quickly identify..

In recent times, Single arm trials are being increasingly used to assess new treatment interventions. They establish..

Recent years have witnessed improving survival outcomes for those struggling with a range of common kidney cancers...

Virtual ISPOR 2020, held November 16 to 19, presented new opportunities for scientific interaction amongst HEOR..

MUCE is a Bayesian solution for cohort expansion trials where multiple dose(s) and multiple indication(s) are tested in..